These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31415187)

  • 1. Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.
    Caverly LJ; Lu J; Carmody LA; Kalikin LM; Shedden K; Opron K; Azar M; Cahalan S; Foster B; VanDevanter DR; Simon RH; LiPuma JJ
    Ann Am Thorac Soc; 2019 Dec; 16(12):1534-1542. PubMed ID: 31415187
    [No Abstract]   [Full Text] [Related]  

  • 2. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
    Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
    PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic footprint of the airway bacterial community in cystic fibrosis.
    Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
    Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
    Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
    PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal and Bacterial Diversity of Airway Microbiota in Adults with Cystic Fibrosis: Concordance Between Conventional Methods and Ultra-Deep Sequencing, and Their Practical use in the Clinical Laboratory.
    Botterel F; Angebault C; Cabaret O; Stressmann FA; Costa JM; Wallet F; Wallaert B; Bruce K; Delhaes L
    Mycopathologia; 2018 Feb; 183(1):171-183. PubMed ID: 28766039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
    Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ
    J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
    Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
    J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergence of bacterial communities in the lower airways of CF patients in early childhood.
    O'Connor JB; Mottlowitz MM; Wagner BD; Boyne KL; Stevens MJ; Robertson CE; Harris JK; Laguna TA
    PLoS One; 2021; 16(10):e0257838. PubMed ID: 34613995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation.
    Twomey KB; Alston M; An SQ; O'Connell OJ; McCarthy Y; Swarbreck D; Febrer M; Dow JM; Plant BJ; Ryan RP
    PLoS One; 2013; 8(12):e82432. PubMed ID: 24358183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
    Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
    ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.
    Stokell JR; Gharaibeh RZ; Hamp TJ; Zapata MJ; Fodor AA; Steck TR
    J Clin Microbiol; 2015 Jan; 53(1):237-47. PubMed ID: 25392361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual Patterns of Complexity in Cystic Fibrosis Lung Microbiota, Including Predator Bacteria, over a 1-Year Period.
    de Dios Caballero J; Vida R; Cobo M; Máiz L; Suárez L; Galeano J; Baquero F; Cantón R; Del Campo R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation.
    Carmody LA; Zhao J; Kalikin LM; LeBar W; Simon RH; Venkataraman A; Schmidt TM; Abdo Z; Schloss PD; LiPuma JJ
    Microbiome; 2015; 3():12. PubMed ID: 25834733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild Cystic Fibrosis Lung Disease Is Associated with Bacterial Community Stability.
    Hampton TH; Thomas D; van der Gast C; O'Toole GA; Stanton BA
    Microbiol Spectr; 2021 Sep; 9(1):e0002921. PubMed ID: 34232099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
    Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
    Microbiol Spectr; 2024 Aug; 12(8):e0078724. PubMed ID: 38916354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.
    Zemanick ET; Wagner BD; Robertson CE; Stevens MJ; Szefler SJ; Accurso FJ; Sagel SD; Harris JK
    Ann Am Thorac Soc; 2015 Feb; 12(2):221-9. PubMed ID: 25474078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis.
    Armbruster CR; Li K; Kiedrowski MR; Zemke AC; Melvin JA; Moore J; Atteih S; Fitch AC; DuPont M; Manko CD; Weaver ML; Gaston JR; Alcorn JF; Morris A; Methé BA; Lee SE; Bomberger JM
    Microbiol Spectr; 2022 Oct; 10(5):e0125122. PubMed ID: 36094193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.
    Sherrard LJ; Einarsson GG; Johnston E; O'Neill K; McIlreavey L; McGrath SJ; Gilpin DF; Downey DG; Reid A; McElvaney NG; Boucher RC; Muhlebach MS; Elborn JS; Tunney MM
    J Cyst Fibros; 2019 Nov; 18(6):808-816. PubMed ID: 30905581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.